Predict your next investment

Corporation
HEALTHCARE | Biotechnology
progenics.com

See what CB Insights has to offer

Business Relationships

10

Service Providers

3

Progenics Pharmaceuticals Service Providers

5 Service Providers

Progenics Pharmaceuticals has 5 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Investment Bank

Bookrunner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Subscribe to see more

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Subscribe to see more

Service Type

Bookrunner

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Progenics Pharmaceuticals Partners & Customers

10 Partners and customers

Progenics Pharmaceuticals has 10 strategic partners and customers. Progenics Pharmaceuticals recently partnered with ROTOP Pharmaka on May 5, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

5/14/2019

Partner

ROTOP Pharmaka

Germany

Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404

`` This European partnership with ROTOP further expands the global reach of our PSMA-targeted prostate cancer portfolio and establishes a development path forward for 1404 in this important market , where SPECT/CT is the standard nuclear imaging modality , '' said Mark Baker , Chief Executive Officer of Progenics Pharmaceuticals , Inc. .

2

1/3/2019

Licensee

Curium

France

Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™

03 , 2019 -- Progenics Pharmaceuticals , Inc. , an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer , and Curium today announced an exclusive agreement to develop and commercialize PyL in Europe .

7

1/3/2019

Licensee

Curium

France

Curium and Progenics Announce European Collaboration for Prostate Cancer Imaging Agent PyL™ - Curium Pharma

-- 3 January 2019 -- Curium , a leading global player in nuclear medicine , and Progenics Pharmaceuticals , Inc. , an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer , today announced an exclusive agreement to develop and commercialize PyL in Europe .

1

7/31/2018

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/3/2018

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

5/14/2019

1/3/2019

1/3/2019

7/31/2018

5/3/2018

Type

Partner

Licensee

Licensee

Licensee

Licensee

Business Partner

ROTOP Pharmaka

Curium

Curium

Country

Germany

France

France

Subscribe to see more

Subscribe to see more

News Snippet

Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404

`` This European partnership with ROTOP further expands the global reach of our PSMA-targeted prostate cancer portfolio and establishes a development path forward for 1404 in this important market , where SPECT/CT is the standard nuclear imaging modality , '' said Mark Baker , Chief Executive Officer of Progenics Pharmaceuticals , Inc. .

Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™

03 , 2019 -- Progenics Pharmaceuticals , Inc. , an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer , and Curium today announced an exclusive agreement to develop and commercialize PyL in Europe .

Curium and Progenics Announce European Collaboration for Prostate Cancer Imaging Agent PyL™ - Curium Pharma

-- 3 January 2019 -- Curium , a leading global player in nuclear medicine , and Progenics Pharmaceuticals , Inc. , an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer , today announced an exclusive agreement to develop and commercialize PyL in Europe .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

7

1

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.